Business Description
IDL Diagnostics AB
ISIN : SE0003883990
Total Employee Number:
25Compare
Compare
Traded in other countries / regions
IDLDX.Sweden80R.Germany IPO Date
2011-05-25Description
IDL Diagnostics AB is a Swedish company that develops and markets blood and urine sample tests. It specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and is established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1 and cytokeratins, to support the treatment of cancers such as breast, prostate, and bladder cancers.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.94 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.71 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.09 | |||||
Beneish M-Score | -2.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.5 | |||||
3-Year EBITDA Growth Rate | 15.3 | |||||
3-Year EPS without NRI Growth Rate | 43.7 | |||||
3-Year FCF Growth Rate | 21.9 | |||||
3-Year Book Growth Rate | -12.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 25.99 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.71 | |||||
9-Day RSI | 50.33 | |||||
14-Day RSI | 48.9 | |||||
3-1 Month Momentum % | 27.45 | |||||
6-1 Month Momentum % | 32.27 | |||||
12-1 Month Momentum % | -11.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.49 | |||||
Quick Ratio | 3.01 | |||||
Cash Ratio | 2.33 | |||||
Days Inventory | 82.88 | |||||
Days Sales Outstanding | 60.65 | |||||
Days Payable | 57.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 2.15 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 46.98 | |||||
Operating Margin % | -33.34 | |||||
Net Margin % | -33.41 | |||||
EBITDA Margin % | -32.94 | |||||
FCF Margin % | -10.76 | |||||
OCF Margin % | -10.76 | |||||
ROE % | -14.02 | |||||
ROA % | -11.99 | |||||
ROIC % | -17.01 | |||||
3-Year ROIIC % | -162.19 | |||||
ROC (Joel Greenblatt) % | -146.92 | |||||
ROCE % | -13.15 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.81 | |||||
PB Ratio | 0.65 | |||||
Price-to-Tangible-Book | 2.22 | |||||
EV-to-EBIT | -4.03 | |||||
EV-to-EBITDA | -4.03 | |||||
EV-to-Revenue | 1.32 | |||||
EV-to-FCF | -12.12 | |||||
Price-to-GF-Value | 0.78 | |||||
| Price-to-Net-Current-Asset-Value | 3.25 | |||||
| Price-to-Net-Cash | 8.44 | |||||
Earnings Yield (Greenblatt) % | -24.77 | |||||
FCF Yield % | -6.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IDL Diagnostics AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 54.561 | ||
| EPS (TTM) (kr) | -0.07 | ||
| Beta | 1.1844 | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.07 | ||
| Volatility % | 68 | ||
| 14-Day RSI | 48.9 | ||
| 14-Day ATR (kr) | 0.023895 | ||
| 20-Day SMA (kr) | 0.42175 | ||
| 12-1 Month Momentum % | -11.13 | ||
| 52-Week Range (kr) | 0.25 - 0.58 | ||
| Shares Outstanding (Mil) | 230.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IDL Diagnostics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IDL Diagnostics AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 113 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 36 days | ||
| General meeting for 2026 | 2026-05-28 11:00 | 0.49 (-3.54%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 0.34 (+6.56%) | ||
| Annual report for 2025 | 2026-04-22 | 0.37 (+4.51%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 0.36 (+5.26%) | ||
| Third quarter earnings results for 2025 | 2025-10-23 | 0.37 (-3.11%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 0.56 (-2.09%) | ||
| General meeting for 2025 | 2025-05-15 11:30 | 0.57 (-3.73%) | ||
| First quarter earnings results for 2025 | 2025-05-07 | 0.60 (+1.69%) |
Show
Entries
IDL Diagnostics AB Frequently Asked Questions
What is IDL Diagnostics AB(OSTO:IDLDX)'s stock price today?
The current price of OSTO:IDLDX is kr0.42. The 52 week high of OSTO:IDLDX is kr0.58 and 52 week low is kr0.25.
When is next earnings date of IDL Diagnostics AB(OSTO:IDLDX)?
The next earnings date of IDL Diagnostics AB(OSTO:IDLDX) is 2026-08-20.
Does IDL Diagnostics AB(OSTO:IDLDX) pay dividends? If so, how much?
IDL Diagnostics AB(OSTO:IDLDX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on IDL Diagnostics AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers